Le Pape P.
Publications
P305
Medical Mycology, 2025, 63, 12.
Multi-fungicide resistance in both clinical and environmental isolates of the human fungal pathogen Aspergillus fumigatus.
https://doi.org/10.1093/mmy/myaf110
P304
Sci Rep, 2025, 16, 2515.
Antifungal and fungicide susceptibility of clinical, animal, and environmental Fusarium and Neocosmospora species from Colombia: a one-health approach.
https://doi.org/10.1038/s41598-025-32234-0
P215
Sci. Rep. 2020, 10, 6211.
In vitro immune responses of human PBMCs against Candida albicans reveals fungal and leucocyte phenotypes associated with fungal persistence.
doi: 10.1038/s41598-020-63344-6
P171
Int. J. Infect. Dis. 2018, 69, 63-67.
First report of sporadic cases of Candida auris in Colombia.
doi: 10.1016/j.ijid.2018.01.034.
P161
Infect. Immun. 2017, 85, e00807-16;
Specific Human and Candida Cellular Interactions Lead to Controlled or Persistent Infection Outcomes During Granuloma-like Formation.
doi: 10.1128/IAI.00807-16.
Autres publications scientifiques
Brevets
B19.
Composition topique à utiliser dans le traitement de la leishmaniose cutanée.
Brevet WO2019043212 - 2019-03-07
B13.
Composés pyridaziniques et pyrroliques non linéaires, procédés d'obtention et applications.
Brevet international CNRS PCT/FR2007/001288.
Thèse